Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Upadacitinib in Moderate to Severe Hidradenitis Suppurativa (Japan)
jRCT2080225263Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Jul 2020
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in hidradenitis suppurativa (HS) comparing Upadacitinib 30 mg with Placebo (2 arms). Primary endpoint: HiSCR response at Week 12. Started Jul 2020; status: completed.
02
Drugs
upadacitinib
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on jRCT2080225263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225263.